Prognostic value of expression of EGFR and nm23 for locoregionally advanced nasopharyngeal carcinoma

Medical Oncology

Volumn 29, Issue 1, 2012, Pages 263-271

  Cao, Xiu Juan ^a   Hao, Jun Fang ^a   Yang, Xin Hua ^a   Xie, Peng ^a   Liu, Lan Ping ^a   Yao, Chun Ping ^a   Xu, Jin ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Epidermal growth factor receptor; Nasopharyngeal carcinoma; nm23; Prognosis

Indexed keywords

NUCLEOSIDE DIPHOSPHATE KINASE NM23; VASCULOTROPIN RECEPTOR;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR BIOPSY;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84864058574     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9782-y     Document Type: Article

References (44)

1. Licitra L, Bernier J, Cvitkovic E, Grandi C, Spinazze S, Bruzzi P, Gatta G, Molinari R. Cancer of the nasopharynx. Crit Rev Oncol Hemato. 2003;45(2):199-213.
2. Titcomb CP Jr. High incidence of nasopharyngeal carcinoma in Asia. J Insur Med. 2001;33(3):235-8.
3. Li XM, Huang WG, Yi H, Cheng AL, Xiao ZQ. Proteomic analysis to identify cytokeratin 18 as a novel biomarker of nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2009;135 (12):1763-75.
4. Ben Nasr H, Chahed K, Remadi S, Zakhama A, Chouchane L. Expression and clinical significance of latent membrane protein-1, matrix metalloproteinase-1 and Ets-1 transcription factor in Tunisian nasopharyngeal carcinoma patients. Arch Med Res. 2009;40(3):196-203.
5. Thariat J, Yildirim G, Mason KA, Garden AS, Milas L, Ang KK. Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. Int J Clin Oncol. 2007;12:99-110. (Pubitemid 46632467)
6. Chua DT, Nicholls JM, Sham JS, Au GK. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(1):11-20. (Pubitemid 38501502)
7. Woodburn Jr. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 1999;82:241-50. (Pubitemid 29255919)
8. Putti TC, To KF, Hsu HC, Chan AT, Lai GM, Tse G, Lee YS, Whang-Peng J, Millward M, Lin L, Lin X, Lee CS. Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohisto-chemical study in the Asia-Pacific region. Histopathology. 2002; 41:144-51. (Pubitemid 34985187)
9. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, Sobel ME. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst. 1988;80: 200-4.
10. Kawakubo Y, Sato Y, Koh T, Kono H, Kameya T. Expression of nm23 protein in pulmonary adenocarcinomas: inverse correlation to tumor progression. Lung Cancer. 1997;17:103-13. (Pubitemid 27261495)
11. Ohta Y, Nozawa H, Tanaka Y, Oda M, Watanabe Y. Increased vascular endothelial growth factor and vascular endothelial growth factor-C and decreased nm23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2000;119:804-13. (Pubitemid 30395479)
12. Guo X, Min HQ, Zeng MS, Qian CN, Huang XM, Shao JY, Hou JH. Nm23-H1 expression in nasopharyngeal carcinoma: correlation with clinical outcome. Int J Cancer. 1998;79(6):596-600. (Pubitemid 28549470)
13. Lee AW, Tung SY, Chua DT. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2010;102(15):1188-98.
14. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. 1998;16:1310-7. (Pubitemid 28175745)
15. Chen Y, Liu MZ, Liang SB, Zong JF, Mao YP, Tang LL, Guo Y, Lin AH, Zeng XF, Ma J. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys. 2008;71(5):1356-64.
16. Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, Kwan WH, Hui EP, Yiu HY, Yeo W, Cheung FY, Yu KH, Chiu KW, Chan DT, Mok TS, Yau S, Yuen KT, Mo FK, Lai MM, Ma BB, Kam MK, Leung TW, Johnson PJ, Choi PH, Zee BC. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2005;97:536-9. (Pubitemid 40590436)
17. Lee AW, Tung SY, Chan AT, Chappell R, Fu YT, Lu TX, Tan T, Chua DT, O'sullivan B, Xu SL, Pang ES, Sze WM, Leung TW, Kwan WH, Chan PT, Liu XF, Tan EH, Sham JS, Siu L, Lau WH. Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006;66(1):142-51. (Pubitemid 44175659)
18. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot JC, Le Mâitre A, Pajak TF, Poulsen MG, O'Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay JH, Pinto LH, Fallai C, Fu KK, Sylvester R, Pignon JP. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a metaanalysis. Lancet. 2006;368:843-54. (Pubitemid 44292807)
19. Caponigro F, Longo F, Ionna F, Perri F. Treatment approaches to nasopharyngeal carcinoma: a review. Anticancer Drugs. 2010;21 (5):471-7.
20. Lin S, Lu JJ, Han L, Chen Q, Pan J. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases. BMC Cancer. 2010;10:39.
21. Yoshida T, Zhang G, Haura EB. Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. Biochem Pharmacol. 2010;80(5):613-23.
22. de La Motte Rouge T, Valent A, Ambrosetti D, Vielh P, Lacroix L. Clinical and molecular predictors of response to EGFR tyro-sine kinase inhibitors in non-small cell lung cancer. Ann Pathol. 2007;27:353-63.
23. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350-6. (Pubitemid 36025259)
24. Wen QH, Miwa T, Yoshizaki T. Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy. Laryngoscope. 1996;106:884-8. (Pubitemid 26242129)
25. Lee CS, Redshaw A, Boag G. Epidermal growth factor immu-noreactivity in human laryngeal squamous cell carcinoma. Pathology. 1997;29:251-4. (Pubitemid 27384831)
26. Maurizi M, Almadori G, Ferrandina G. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer. 1996;74:1253-7. (Pubitemid 26360115)
27. Grandis JR, Melhem MF, Gooding WE. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90:824-32. (Pubitemid 28280548)
28. Ma B, Hui EP, King A, To KF, Mo F, Leung SF, Kam M, Lo YM, Zee B, Mok T, Ahuja A, Chan AT. A phase II study of patients with metastatic or locoregionally recurrent nasopharyn-geal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. Cancer Chemother Pharmacol. 2008;62(1):59-64. (Pubitemid 351537846)
29. Taheri-Kadkhoda Z, Magnusson B, Svensson M, Mercke C, Björk-Eriksson T. Expression modes and clinical manifestations of latent membrane protein 1, Ki-67, cyclin-B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinoma. Head Neck. 2009;31(4):482-92.
30. Cojocariu OM, Huguet F, Lefevre M, Périé S. Prognosis and predictive factors in head-and-neck cancers. Bull Cancer. 2009; 96(4):369-78.
31. Geoerger B, Gaspar N, Opolon P, Morizet J, Devanz P, Lecluse Y, Valent A, Lacroix L, Grill J, Vassal G. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts. Int J Cancer. 2008;123(1):209-16. (Pubitemid 351705211)
32. Ping Y, Jian Z, Yi Z, Huoyu Z, Feng L, Yuqiong Y, Shixi L. Inhibition of the EGFR with nanoparticles encapsulating anti-sense oligonucleotides of the EGFR enhances radiosensitivity in SCCVII cells. Med Oncol. 2010;27(3):715-21.
33. Chen CC, Chen WC, Lu CH, Wang WH, Lin PY, Lee KD, Chen MF. Significance of interleukin-6 signaling in the resistance of pharyngeal cancer to irradiation and the epidermal growth factor receptor inhibitor. Int J Radiat Oncol Biol Phys. 2010;76(4): 1214-24.
34. Choi EJ, Ryu YK, Kim SY, Wu HG, Kim JS, Kim IH, Kim IA. Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response. Mol Cancer Res. 2010;8(7):1027-36.
35. Akimoto T. Molecular basis and clinical results of radiation therapy combined with molecular targeted therapy. Nippon Rin-sho. 2010;68(6):1025-34.
36. Kim JE, Lee DH, Choi Y, Yoon DH, Kim SW, Suh C, Lee JS. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer. 2009;65(3):351-4.
37. Bernier J, Bonner J, Vermorken JB, Bensadoun RJ, Dummer R, Giralt J, Kornek G, Hartley A, Mesia R, Robert C, Segaert S, Ang KK. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol. 2008;19(1): 142-9.
38. Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol. 2010;17(3):37-48.
39. Razak AR, Siu LL, Le Tourneau C. Molecular targeted therapies in all histologies of head and neck cancers: an update. Curr Opin Oncol. 2010;22(3):212-20.
40. Sgouros J, Galani E, Gonos E, Moutsatsou P, Belechri M, Skarlos D, Dionyssiou-Asteriou A. Correlation of nm23-H1 gene expression with clinical outcome in patients with advanced breast cancer. In Vivo. 2007;21(3):519-22. (Pubitemid 46901412)
41. Pasz-Walczak G, Salagacka A, Potemski P, Balcerczak E, Kordek R, Mirowski M. Maspin and Nm23-H1 expression in colorectal cancer. Neoplasma. 2010;57(2):95-101.
42. Guo H, Nan K, Hu T, Meng J, Hui W, Zhang X, Qin H, Sui C. Prognostic significance of co-expression of nm23 and p57 protein in hepatocellular carcinoma. Hepatol Res. 2010. doi:10.1111/j.1872-034X.2010.00721.x.
43. Tham IW, Lu JJ. Controversies and challenges in the current management of nasopharyngeal cancer. Expert Rev Anticancer Ther. 2010;10(9):1439-50.
44. Huang GW, Mo WN, Kuang GQ, Nong HT, Wei MY, Sunagawa M, Kosugi T. Expression of p16, nm23-H1, E-cadherin, and CD44 gene products and their significance in nasopharyngeal carcinoma. Laryngoscope. 2001;111(8):1465-71. (Pubitemid 32730196)